Original language | English (US) |
---|---|
Pages (from-to) | 253-255 |
Number of pages | 3 |
Journal | JACC: Clinical Electrophysiology |
Volume | 7 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2021 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JACC: Clinical Electrophysiology, Vol. 7, No. 2, 02.2021, p. 253-255.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Prevalence of Suicide Among Patients With Sudden Death–Predisposing Genetic Heart Diseases
AU - Niaz, Talha
AU - Saunders, Michaela
AU - Bos, J. Martijn
AU - Campbell, Robert M.
AU - Ackerman, Michael J.
N1 - Funding Information: This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program and Mayo Clinic CCaTS through grant number UL1TR002377 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health. Dr. Ackerman is a consultant for Abbott, ARMGO, Audentes Therapeutics, Biotronik, Boston Scientific, Daiichi-Sankyo, Invitae, LQT Therapeutics, Medtronic, MyoKardia, and UpToDate. Dr. Ackerman and Mayo Clinic have an equity/royalty relationship with AliveCor Inc. None of these entities provided funding for this study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program and Mayo Clinic CCaTS through grant number UL1TR002377 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health. Dr. Ackerman is a consultant for Abbott, ARMGO, Audentes Therapeutics, Biotronik, Boston Scientific, Daiichi-Sankyo, Invitae, LQT Therapeutics, Medtronic, MyoKardia, and UpToDate. Dr. Ackerman and Mayo Clinic have an equity/royalty relationship with AliveCor Inc. None of these entities provided funding for this study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2021/2
Y1 - 2021/2
UR - http://www.scopus.com/inward/record.url?scp=85100695930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100695930&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2020.10.007
DO - 10.1016/j.jacep.2020.10.007
M3 - Letter
C2 - 33602408
AN - SCOPUS:85100695930
SN - 2405-500X
VL - 7
SP - 253
EP - 255
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 2
ER -